UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (170) 170
science & technology (170) 170
oncology (162) 162
humans (141) 141
female (102) 102
male (94) 94
middle aged (81) 81
respiratory system (81) 81
carcinoma, non-small-cell lung - drug therapy (80) 80
aged (79) 79
lung neoplasms - drug therapy (79) 79
adult (74) 74
lung neoplasms - pathology (68) 68
lung neoplasms - genetics (63) 63
carcinoma, non-small-cell lung - genetics (61) 61
carcinoma, non-small-cell lung - pathology (58) 58
protein kinase inhibitors - therapeutic use (58) 58
mutation (50) 50
crizotinib (46) 46
aged, 80 and over (44) 44
antineoplastic agents - therapeutic use (38) 38
lung cancer (38) 38
lung cancer, non-small cell (38) 38
pulmonary and respiratory medicine (36) 36
pyridines - therapeutic use (33) 33
pyrazoles - therapeutic use (32) 32
hematology, oncology and palliative medicine (30) 30
neoplasm staging (30) 30
prognosis (30) 30
treatment outcome (29) 29
retrospective studies (27) 27
non-small cell lung cancer (26) 26
gene rearrangement (24) 24
lung neoplasms - mortality (23) 23
nsclc (23) 23
receptor protein-tyrosine kinases - genetics (23) 23
genetic aspects (21) 21
pulmonary/respiratory (21) 21
carcinoma, non-small-cell lung - mortality (20) 20
drug resistance, neoplasm - genetics (20) 20
young adult (20) 20
alectinib (19) 19
receptor protein-tyrosine kinases - antagonists & inhibitors (19) 19
research (18) 18
carcinoma, non-small-cell lung - enzymology (17) 17
disease progression (17) 17
lung neoplasms - enzymology (17) 17
metastasis (17) 17
cancer (16) 16
care and treatment (16) 16
medical colleges (16) 16
chemotherapy (15) 15
molecular targeted therapy (15) 15
protein kinase inhibitors - adverse effects (15) 15
protein kinase inhibitors - pharmacology (15) 15
anaplastic lymphoma kinase (14) 14
carbazoles - therapeutic use (14) 14
disease-free survival (14) 14
patients (14) 14
piperidines - therapeutic use (14) 14
survival rate (14) 14
antineoplastic agents - adverse effects (13) 13
non-small cell lung carcinoma (13) 13
proto-oncogene proteins c-met - genetics (13) 13
receptor, epidermal growth factor - genetics (13) 13
tyrosine (13) 13
adenocarcinoma - genetics (12) 12
adolescent (12) 12
lung neoplasms - diagnosis (12) 12
lung neoplasms - therapy (12) 12
proto-oncogene proteins - genetics (12) 12
respiratory tract diseases (12) 12
adenocarcinoma - pathology (11) 11
alk (11) 11
analysis (11) 11
animals (11) 11
erbb receptors - genetics (11) 11
follow-up studies (11) 11
health aspects (11) 11
kaplan-meier estimate (11) 11
pyrazoles - adverse effects (11) 11
pyridines - adverse effects (11) 11
文学作品 (11) 11
abridged index medicus (10) 10
brain neoplasms - secondary (10) 10
cancer therapies (10) 10
comprehensive genomic profiling (10) 10
drug resistance, neoplasm (10) 10
drug therapy (10) 10
general & internal medicine (10) 10
hemic and lymphatic diseases (10) 10
oncogene proteins, fusion - genetics (10) 10
protein-tyrosine kinases - genetics (10) 10
targeted therapy (10) 10
tumors (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
brain neoplasms - drug therapy (9) 9
california cancer registry (9) 9
genomics - methods (9) 9
in situ hybridization, fluorescence (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Pharmaceutical industry | Lymphoma | Lung cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 10/2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. 15 - 26
Journal Article